RT journal article T1 A Scoping Review of Creatine Supplementation in Alzheimer’s Disease: Evidence from Preclinical and Clinical Studies A1 Cordero Choquet de Isla, Javier A1 Riscart López, Javier A1 Sanchez Gomar, Ismael A1 Bandez Ruiz, Manuel Jesús A1 Rosety Rodríguez, Ignacio A1 Brenes Martín, Francisco A1 Bazán, Nicolás G. A1 Navarro Quiroz, Elkin A1 ROSETY RODRÍGUEZ, Miguel Ángel A1 Geribaldi Doldán, Noelia A2 Anatomía y Embriología Humana A2 BiomedicinaBiotecnología y Salud Pública A2 Didáctica de la Educación FísicaPlástica y Musical A2 Medicina K1 ageing K1 Alzheimer’s disease K1 neurodegeneration K1 creatine K1 nutrition K1 bioenergetics K1 preclinical models AB Background/Objectives: Although creatine supplementation has a theoretical rationale for neuroprotection, public interest has outpaced available scientific evidence. Alzheimer’s disease (AD), a major and growing global health concern, is among the neurodegenerative diseases proposed to benefit from creatine supplementation. This scoping review systematically maps the existing literature on creatine supplementation for AD to identify gaps that limit translational progress. Methods: Following JBI methodology and PRISMA-ScR guidelines, a search in five electronic databases was conducted for preclinical and clinical studies evaluating creatine interventions in AD. The methodological quality of the studies was appraised using the SYRCLE and NIH tools, respectively. Results: Nine unique studieswere included. The preclinical models investigated neuron apoptosis, oxidative stress, neuroinflammation, mitochondrial function, cognitive outcomes, and pathophysiological clearance. Conversely, clinical studies were limited to a pilot trial that suggested preliminary tolerability but could not establish causality. This review identifies six limitations within the current evidence: (1) a reliance on acute or non-transgenic animal models that lack construct validity; (2) a need to address sexual dimorphism; (3) a lack of studies exploring administration routes to bypass the blood–brain barrier; (4) a complete lack of independent randomized controlled trials (RCTs), with all clinical evidence originatingfrom a single research group; (5) an absence of research assessing creatine as a preventive strategy; and (6) a shortage of assessment regarding physical syndromes, such as frailty. Conclusions: The scientific evidence for creatine in AD remains preliminary. Future research should prioritize progressive transgenic models, evaluate noninvasive administration routes, investigate effects on frailty, assess long-term preventive efficacy, account for sex as a variable, and transition to rigorous RCTs. PB MDPI (Multidisciplinary Digital Publishing Institute) SN 2072-6643 YR 2026 FD 2026-10-23 LK http://hdl.handle.net/10498/40658 UL http://hdl.handle.net/10498/40658 LA eng DS Repositorio Institucional de la Universidad de Cádiz RD 16-nov-2026